BioAge Labs (BIOA) Depreciation & Amortization (CF) (2023 - 2026)
BioAge Labs' (BIOA) quarterly Depreciation & Amortization (CF) came in at $70000.0 in Q2 2026, up 20.69% year-over-year from $58000.0 in Q2 2025, and up 11.11% quarter-over-quarter from $63000.0 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Depreciation & Amortization (CF) across 4 years of filings, most recently posting $70000.0 for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 20.69% year-over-year to $70000.0; the TTM figure through Jun 2026 stood at $251000.0 (up 39.44% YoY), while the FY2025 annual figure was $213000.0, up 27.54% from the prior year.
- Depreciation & Amortization (CF) came in at $70000.0 for Q2 2026 at BioAge Labs, up from $63000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $70000.0 in Q2 2026 to a low of $33000.0 in Q1 2024.
- Average Depreciation & Amortization (CF) over 4 years is $50363.6, with a median of $49000.0 recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) grew 12.12% in 2025 and soared 70.27% in 2026.
- Over 4 years, Depreciation & Amortization (CF) stood at $41000.0 in 2023, then climbed by 14.63% to $47000.0 in 2024, then jumped by 46.81% to $69000.0 in 2025, then grew by 1.45% to $70000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $70000.0 in Q2 2026, $63000.0 in Q1 2026, and $69000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn | 600,000.00 |
| 10 | BioAge Labs | 397.27 Mn | 397.27 Mn | -14.23 Mn | 70,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70,000.00 |
| Mar 31, 2026 | 63,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 49,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 41,000.00 |